Lantern Pharma Inc. LTRN
1.22
0.01
0.83%
as of 25 Sep
- Market cap
- $15.5M
- P/E
- 0.0×
Follow LTRN
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
1.96 | 1.87 | 2.40 | 3.33 |
+8 more quarters Free account |
Net Debt/EBITDA |
2.10 | 1.86 | 2.40 | 2.74 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.42 | 1.13 | 0.69 | 1.09 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.24) | (0.34) | (0.26) | (0.42) | |
Cash per Share |
0.59 | 0.56 | 0.93 | 1.14 | |
Shareholders Equity per Share |
(0.26) | 0.31 | 0.60 | 0.89 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.26) | 0.31 | 0.60 | 0.89 | |
Free Cash Flow |
(2.94) | (3.77) | (2.79) | (4.57) | |
Working Capital |
4.14 | 3.28 | 6.30 | 9.42 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
(3.36) | 3.28 | 6.30 | 9.42 | |
| Other line items | |||||
Quick Ratio |
1.70 | 1.67 | 2.25 | 3.06 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.24) | (0.34) | (0.26) | (0.42) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
4.52 | 3.92 | 4.28 | 3.67 | |
Average Assets |
13.01 | 14.16 | 18.30 | 21.96 | |
Average Common Equity |
4.65 | 10.11 | 13.86 | 18.09 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates